- Home
- STSS vs VRAX Comparison
STSS vs VRAX Comparison
Compare STSS & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STSS
- VRAX
- Stock Information
- Founded
- STSS 2017
- VRAX 2013
- Country
- STSS United States
- VRAX United Kingdom
- Employees
- STSS N/A
- VRAX N/A
- Industry
- STSS Medical/Dental Instruments
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- STSS Health Care
- VRAX Health Care
- Exchange
- STSS Nasdaq
- VRAX Nasdaq
- Market Cap
- STSS 6.9M
- VRAX 7.8M
- IPO Year
- STSS 2022
- VRAX 2022
- Fundamental
- Price
- STSS $1.92
- VRAX $1.78
- Analyst Decision
- STSS
- VRAX
- Analyst Count
- STSS 0
- VRAX 0
- Target Price
- STSS N/A
- VRAX N/A
- AVG Volume (30 Days)
- STSS 384.2K
- VRAX 369.4K
- Earning Date
- STSS 11-14-2024
- VRAX 02-05-2025
- Dividend Yield
- STSS N/A
- VRAX N/A
- EPS Growth
- STSS N/A
- VRAX N/A
- EPS
- STSS N/A
- VRAX N/A
- Revenue
- STSS N/A
- VRAX $84,872.00
- Revenue This Year
- STSS N/A
- VRAX $5,169.18
- Revenue Next Year
- STSS N/A
- VRAX $66.97
- P/E Ratio
- STSS N/A
- VRAX N/A
- Revenue Growth
- STSS N/A
- VRAX 7.03
- 52 Week Low
- STSS $1.70
- VRAX $0.60
- 52 Week High
- STSS $18.15
- VRAX $9.00
- Technical
- Relative Strength Index (RSI)
- STSS 34.45
- VRAX 47.15
- Support Level
- STSS $1.81
- VRAX $1.51
- Resistance Level
- STSS $2.15
- VRAX $2.38
- Average True Range (ATR)
- STSS 0.21
- VRAX 0.21
- MACD
- STSS -0.02
- VRAX 0.01
- Stochastic Oscillator
- STSS 32.53
- VRAX 27.83
About STSS Sharps Technology Inc.
Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes are designed to eliminate potentially infectious and accidental needlestick injuries.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.